July 25th Options Now Available For Sarepta Therapeutics (SRPT)

Analysis of Sarepta Therapeutics (SRPT) options reveals potential yield-boosting strategies for investors; selling the $38 put offers an 8.68% return if it expires worthless, with a 59% probability based on current analytics, while a covered call strategy at the $41 strike yields 9.92% if the stock is called away, but carries a 51% chance of expiring worthless and providing a 5.60% premium boost. The implied volatility for the put and call options are 88% and 84% respectively, compared to the stock's 72% trailing twelve month volatility.

Analysis

The provided financial text details two specific options strategies for Sarepta Therapeutics (SRPT), which was trading at $39.30 per share at the time of writing. For investors interested in acquiring SRPT, selling the $38.00 strike put contract, with a current bid of $3.30, offers an alternative entry strategy; this approach results in an effective cost basis of $34.70 per share if the option is exercised, or an 8.68% return on the cash commitment (a 63.39% annualized 'YieldBoost') if the put expires worthless. The probability of this $38.00 strike put, which is approximately 3% out-of-the-money, expiring worthless is currently estimated at 59%. For existing SRPT shareholders, selling a covered call at the $41.00 strike price, with a current bid of $2.20, presents an income-generating opportunity. This strategy could yield a total return of 9.92% if the stock is called away at the July 25th expiration, or provide a 5.60% premium boost (a 40.87% annualized 'YieldBoost') if the call expires worthless, an outcome with an estimated 51% probability. This $41.00 strike is approximately 4% out-of-the-money. The article highlights that the implied volatility for the put contract is 88% and for the call contract is 84%, both figures being notably higher than SRPT's actual trailing twelve-month volatility of 72%, indicating that option premiums are relatively elevated compared to historical price movements.

Key Decisions for Investors

• Investors considering initiating a position in Sarepta Therapeutics (SRPT) at a price below the current $39.30 market level could evaluate selling the $38.00 strike put, aiming for an effective purchase price of $34.70 if assigned, or to collect an 8.68% premium if the option expires unexercised.
• Current SRPT shareholders seeking to generate income and willing to cap potential upside might consider selling the $41.00 strike covered call, which offers a 9.92% return if shares are called away by the July 25th expiration, or a 5.60% premium (YieldBoost) if the option expires worthless.
• The observed implied volatilities of 88% for puts and 84% for calls, which exceed SRPT's 72% trailing twelve-month historical volatility, suggest that option selling strategies may offer enhanced yields due to richer premiums, but this also reflects heightened market expectations for future price volatility that must be incorporated into risk assessments.
• Investors should carefully weigh the stated probabilities of the options expiring worthless (59% for the put, 51% for the call) and acknowledge that these are estimates that can change, necessitating a thorough review of SRPT's underlying business fundamentals and overall market conditions before committing to these strategies.